The Brain Energy hypothesis — most clearly articulated in recent years by Chris Palmer at Harvard McLean — proposes that mitochondrial dysfunction is the common substrate underlying a wide range of psychiatric disorders. The framework argues that depression, bipolar disorder, schizophrenia, anxiety disorders, and certain neurodegenerative conditions are not separate entities with separate mechanisms but rather different surface presentations of a common underlying metabolic disturbance: the inability of brain cells to produce or use energy effectively. The hypothesis has accumulated substantial supporting evidence and is reshaping how a growing number of clinicians think about both the biology of psychiatric illness and its treatment.
Mitochondria are the energy factories of cells, producing ATP through oxidative phosphorylation. The brain consumes approximately 20% of the body's energy despite being only 2% of body weight, and neurons in particular are exquisitely dependent on consistent mitochondrial function for synaptic transmission, neurotransmitter synthesis, membrane potential maintenance, and the chronic energy demands of complex cognition. When mitochondrial function degrades — through aging, inflammation, insulin resistance, oxidative stress, toxin exposure, chronic stress, or nutritional deficiency — the cells most affected first are those with the highest baseline energy demand, which are neurons.
The evidence base is multimodal. Direct measurement of mitochondrial function in patients with depression, bipolar disorder, and schizophrenia consistently shows abnormalities — reduced ATP production, altered membrane potential, fragmented mitochondrial morphology. Pharmacological agents effective in psychiatric conditions (lithium, valproate, some antidepressants, ketamine) have well-characterized effects on mitochondrial function in addition to their classical neurotransmitter effects. Conditions known to involve primary mitochondrial dysfunction (mitochondrial diseases) frequently present with psychiatric symptoms. The convergence across multiple lines of evidence is the strength of the hypothesis.
The clinical implication is that interventions that improve mitochondrial function should improve psychiatric symptoms, and the evidence increasingly supports this prediction. Aerobic exercise, which is among the most consistently effective interventions for depression, improves mitochondrial biogenesis. Ketogenic diets, which provide an alternative fuel substrate that some impaired mitochondria handle more efficiently than glucose, have shown remarkable effects in refractory cases of bipolar disorder, depression, and even psychosis in case series and small trials. Sleep optimization, intermittent fasting, cold exposure, and certain supplements (CoQ10, creatine, NAD precursors) all have mitochondrial mechanisms of action and varying levels of evidence for psychiatric benefit.
The framework reframes psychiatric medication. Many existing psychiatric medications work in part through mitochondrial effects, even when classical pharmacology focuses on neurotransmitter receptors. Lithium upregulates mitochondrial biogenesis. Ketamine's rapid antidepressant effect may involve mitochondrial activation as much as glutamate receptor antagonism. The brain energy lens suggests evaluating both established and novel agents for their metabolic effects, not just their receptor effects — a shift in how the pharmacology is conceptualized.
The longevity-psychiatry implication is direct. Mitochondrial dysfunction is also among the central mechanisms of cognitive aging — declining mitochondrial efficiency in neurons is one of the early biochemical signatures of cognitive decline. Interventions that preserve mitochondrial function therefore serve both psychiatric symptom relief and cognitive longevity. The patient with refractory depression treated with a metabolic intervention is being treated for both the present illness and the future trajectory. This is the unification that the Brain Energy framework offers — and the reason it is reshaping the field.